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Rezumat
Introducere. Obiectivul studiului este de a 
determina relaţia dintre factorii de creştere 
similari insulinei (IGF-1) şi ateroscleroza 
coronariană.
Materiale şi metode. În studiu au fost incluşi 
30 de pacienţi cu angiografie coronariană 
normală şi 43 de pacienţi supuşi angioplast-
iei coronariene transluminale percutanate 
(PTCA). Grupurile de studiu au fost formate 
din bolnavi care s-au adresat la Departamen-
tul de Cardiologie al Facultăţii de Medicină 
din cadrul GATA. Probele de sânge au fost 
recoltate din artera coronariană în prima 
etapă a angiografiei, înainte de introducerea 
substanţei de contrast.
Rezultate. Nivelurile medii ale IGF-1 în 
primul grup cu angiografie coronariană 
normală şi în al doilea grup supus PTCA au 
fost 222,05, respectiv 686,15. Rezultatele erau 
semnificative sub aspect statistic. O creştere 
semnificativă din punct de vedere statistic 
în nivelurile IGF-1 a fost determinată în cel 
de-al doilea grup (p=0,000). De asemenea, 
variaţiile din rezultatele electrocardiogra-
fice (ECG) au fost semnificative în cadrul 
aceluiaşi grup (p=0,002).
Concluzii: Nivelurile IGF-1 ale pacienţilor 
supuşi PTCA au fost mai mari decât rezul-
tatele studiilor similare precedente, acest 
lucru fiind determinat de modul în care am 
recoltat probele de sânge, adică direct din 
artera coronariană. Considerăm că această 
creştere a nivelurilor IGF-1 este generată de 
mecanismul de compensare locală, declanşat 
în inima afectată de ischemie.
Cuvinte-cheie: factori de creştere similari 
insulinei (IGF-1), angioplastie coronariană 
transluminală percutanată (PTCA), 
insuficienţă coronariană.
Introduction
Several factors play role in the physiopathology of coronary 
aterosclerosis and endohelium dysfunction, lipids, genetic fac-
tors, environmental and metabolic factors plays mediator role. 
Experimental and clinical studies indicate that growth hormone 
(GH) and insulin like growth factor–1 (IGF–1) play a role in the 
development of the cardiovascular system [1–3]. 
IGF–1 has a similar structure as proinsulin, it is a polypep-
tide consisting of 70 amino acids. IGF–1 and its receptors are 
found in various tissues, such as myocard, vessel endothelium 
and vessel smooth muscles. It has been demonstrated that IGF–1 
has endocrine, paracrine and otocrine effects via a complex 
system [1].
It is known that IGF–1 has a positive effect over the deve-
lopment of cardiac structures and function of contraction and 
fraction of ejection. According to previously done experimental 
studies revealed that IGF–1 has increased cardiac contraction 
and performance, at the same time decreasing cardiac wall 
stress [2]. 
IGF–1 is a primary mediator which demonstrates the ef-
fects of growth hormone (GH) and has a regulatory function of 
cellular proliferation, differentiation, and apopytosis. It is also 
known that deficiencies of GH and IGF–1 are closely related with 
early atherosclerosis and high cardiovascular disease mortality 
rate [1]. 
It is also apparent that hypopituitarism with GH and IGF–1 
deficiencies causes endothelial dysfunction and premature athe-
rosclerosis and these cases are reversible with GH replacement 
[4]. Cardiovascular diseases’ mortality is doubled in GH/IGF–1 
deficiencies [5]. Furthermore, recent epidemiologic studies 
demonstrate that subnormal IGF–1 levels increase the risk of 
acute myocardial infarct (AMI) and carotid atherosclerosis. It 
is thought that IGF1’s cardiovascular disease protection effect 
is because of its effect over myocyte survival, atherosclerotic 
plaque stability and endothelial function [6].
While insulin and GH stimulate IGF–1 secretion, inter-
leukin–1 (IL–1) and cortisol inhibit it [7–8]. Additionally, IGF–1 
regulates glucose metabolism by lowering insulin levels and 
increasing insulin sensitivity and it effects lipid profiles in a 
positive way [9]. 
According to studies completed since 1992, GH and IGF–1 
are in series of events related with heart development and 
hypertrophism, which are related to cardiovascular diseases 
and risk factors (hypertrygliseridemia, obesity and glucose in-
tolerance[10–11]. 
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Both IGF–1 and IGF–2 take a role in cardiac 
protein synthesis stimulation, in the level of plasma 
stability and act like a buffer in the protein synthesis 
[12].
Purpose of this study is to determine the in-
crease in the blood levels of IGF–1 due to coronary 
artery disease. 
Material and Method
Elective coronary angiography was administe-
red in this study to 73 participants suspect of having 
coronary artery disease and not undergoing any 
medical treatment. There are two categories of parti-
cipants, participants who had some type of coronary 
artery lesions (atherosclerosis) and participants who 
were completely normal. According to this, 30 par-
ticipants were in group 1, or the completely normal 
group and group 2 was composed of 43 participants 
who had atherosclerosis.
According to the JNC–7 (The Seventh Report 
of the Joint National Committee) guide, participants 
who had artery blood pressure of more than 140/90 
mm/Hg. and ADA (American Diabetes Association) 
the diagnosis of diabetes mellitus which is accepted 
as a hunger blood sugar level of over 126 mg/dl were 
not included to our study.
The blood samples were collected in the first 
phase of angiography and just before contrast sub-
stance delivery, and after PTCA guiding catheter was 
placed to coronary artery. A blood sample of appro-
ximately 5.0 mL was placed into sterile preservative-
free test tubes. The blood was centrifuged at a speed 
of 2.500 rpm for 45 minutes. The serums obtained 
were stored in -80C deep-freeze conditions until the 
study day. The samples obtained in one month were 
used in a maximum of 40 days. 
Serum levels of IGF–1 were determined by IRMA 
techniques and Nonextraction IGF–1 IRMA (Diagnos-
tic Systems Laboratories-USA) in consecutive groups. 
Serum glucose level has been calculated from these 
serum samples the day they were taken with the help 
of photometric-colorimetric kit.
In statistitical analyses continuous variables 
were presented with mean-standard deviation 
and other variables with percentage. Chi-squa-
re test and Mann Whitney U test for transient 
variables and continuous variables were used, 
respectively.
Results
16 female (21,9%) and 57 male (78,1%) indi-
viduals were included to the study No significant 
difference was observed between groups in terms of 
sex (p=0,1666) (Table 1). Age disturbances of groups 
were shown in (table 2).
Table 1





n % n % n %
0,163
Normal 9 30,0 21 70,0 30
100
PTCA 7 16,3 36 83,7 43
Total 16 21,9 57 78,1 73 100
Table 2




45 year 45-65 year
Over 
65 year
Normal n 8 13 9 30
0.035
PTCA 
% 26,7 43,3 30,0 100,0
n 4 18 21 43
Total
% 9,3 41,9 48,8 100,0
n 12 31 30 73
% 16,4 42,5 41,1 100,0
Also no significant difference was observed 
between groups according to kidney(urea, creati-
nine), liver function tests (AST, ALT) and lipid profile 
(cholesterole, triglyceride, HDL, LDL) (table 3). 
Table 3
Comparison of renal functions, hepatik functions 
tests, lipid profile among the groups
Groups n Mean Standart deviation p
Urea
Normal 30 33,00 10,31
0.231
PTCA 43 36,40 13,70
Creatin
Normal 30 ,9967 ,1866
0.735
PTCA 43 1,0140 ,2479
AST
Normal 30 20,37 6,40
0.219
PTCA 43 26,91 33,56
ALT
Normal 30 22,03 11,81
0.454
PTCA 43 24,28 13,48
Cholesterol
Normal 30 184,77 40,57
0.582
PTCA 43 190,07 39,97
Triglyceride
Normal 30 147,70 58,70
0.600
PTCA 43 140,23 60,67
HDL
Normal 30 44,27 10,65
0.696
PTCA 43 43,30 9,86
LDL 
Normal 30 106,92 33,33
0.060
PTCA 43 121,51 29,99
Average levels of IGF–1 were 496.66+/-376.70; 
ıt was 225.05+/-203.25 in group 1 686,15+/-353,95 
in group 2. Levels of IGF–1 were significantly higher 
in group 2 (table 4). 
48
S T U D I I  C L I N I C O - ŞT I I N Þ I F I C E
Table 4
Comparison of IGF–1 levels





Normal 30 225.05 203.25 9.10 868.50
<0.001PTCA 43 686.15 353.95 79.90 1415.00
TOTAL 73 496.66 376.70 9.10 1415.00
According to ischemic alterations in electrocar-
diographic examination, findings were significantly 
apparent in group 2 (table 5). 
Table 5






Normal n 6 24 30 0.002
PTCA
% 20,0% 80,0% 100,0%
n 24 19 43
Total
% 55,8% 44,2% 100,0%
n 30 43 73
% 41,1% 58,9% 100,0%
Discussion
Recent epidemiologic studies concluded that 
IGF-1 levels in patients with a diagnois of MI is found 
to be lower due to the control group in two cross-
sectional studies. IGF–1 levels of patients with a 
diagnose of acute coronary artery disease found to 
be lower than the control group. 
In two similar evidence based studies IGF–1 
levels of patients who were hospitalized with a 
diagnose of AMI is our found to be lower than the 
control group [8–13]. In the results of these studies 
the levels of IGF binding protein 3 is found to be 
significantly higher in AMI cases [14,15]. In Dan Mo-
nika study which is the only prospective study, the 
relative risk of coronary heart disease onset is found 
1.65 in patients with a low IGF–1 level. According to 
Dan Monica study results, the partial risk of coronary 
artery disease has been determined as 4.07 for IGF–1 
level of low 25% and IGF-binding protein 3 high 25% 
[16]. IGF–1 induces vasculary smooth muscle prolife-
ration and migration. In study models after vascular 
amate intimal hiperplazi develops due to decreased 
IGF–1 levels [17, 18]. IGF–1 and other sonata staton 
analog G Factors causes restenosis after angioplasty 
[19–20]. Its known that growth hormone realizes its 
effects such as mitogenic effect true IGF–1 [6]. Its an 
excellent indicator to determine GH level indirectly 
due to its long half life and diurnal stability compared 
to GH. Serum IGF–1 levels decreased by age and for 
people over age of 65, ıts levels are 50% less than 
the young adults [21]. 
Mean level of IGF is 560.27 for patients betwe-
en age of 45–65 years. Patients older than 55 years, 
mean level turns out to be 489.87. However it is 
insignificant and our result is discordant with the 
previous reports mentioning to decrease in the levels 
of IGF–1 by aging. This may be related to insufficient 
number of participants in our study. 
The receptors of myocardial cells can express 
GH and IGF–1 therefore GH realize its effects on 
the heart directly both local and systemic IGF–1 in-
duction [3].
In a study group consisting of 87 patients with a 
diagnosis of coronary artery disease both blood and 
cardiac IGF–1 levels were examined. The cardiac IGF–1 
levels were found to be increasing and the blood 
IGF–1 levels were found to be decreasing. A negative 
correlation between ejection fraction and cardiac 
IGF–1 levels is determined. Due to these results, the 
compensator mechanism which regulates the left 
ventrical dysfunction also led cardiac IGF–1 [22].
In Dan-Monika Cohort Study IGF–1 levels were 
examined before the coronary event. Even though 
at first the risk decreased, it was later found in this 
study that as IGF–1 levels decreased, the risk in-
creased [16].
In our study,  coronary levels of IGF in patients 
underwent to PTCA were significantly higher than 
that of previous reports. Difference may related to 
our way of blood sample collection directly from the 
coronary vessels. Due to our results, we can conclu-
de that the heart may develop local compensatory 
mechanisms to increase IGF–1 levels in ischemic 
cardiac events.  IGF–1 levels may increase in heart 
and related vessels to regulate the heart function. 
In conclusion, a comprehensive, long-term 
study with a large number of participants is required. 
to establish the function of IGF–1 in patients with 
coronary artery disease. 
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